The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score

Foster, Jason M.; Smith, Lynette M.; Ceelen, Wim; Deraco, Marcello; Yıldırım, Yusuf; Levine, Edward A.; Muñoz-Casares, Cristóbal; Gléhen, Olivier; Patel, Amie; Esquivel, Jesús

doi:10.1002/jso.24406

Cited by 22 publications

(10 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, for patients with colorectal, ovarian, high-grade appendix, and mesothelial tumors, selecting patients with a peritoneal carcinoma index score of less than 25 is important in achieving long-term survival. 27 , 28 , 29 , 30 , 31 , 32 This also enables surgeons performing CRS/HIPEC to achieve optimal surgical cytoreduction, which is paramount in and predictive of long-term survival. 29 Additionally, surgeons who perform CRS/HIPEC in the United States are a small community who primarily perform these procedures at high-volume centers because only a limited number of institutions and medical centers are equipped or willing to invest in a CRS/HIPEC program.…”

Section: Discussionmentioning

confidence: 99%

Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures

et al. 2019

Self Cite

View full text Add to dashboard Cite

Key Points Question What are the morbidity and mortality of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) compared with other major oncologic surgical procedures? Findings In this cohort study of 1822 patients who received CRS/HIPEC compared with patients who received other high-risk surgical oncology procedures, overall 30-day mortality was lower in CRS/HIPEC (1.1%) compared with pancreaticoduodenectomy (2.5%), right lobe hepatectomy (2.9%), esophagectomy (3.0%), and trisegmental hepatectomy (3.9%). Meaning Comparative analysis revealed CRS/HIPEC to be safe across the spectrum of National Surgical Quality Improvement Project safety metrics when compared with oncologic procedures with similar inherent risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Only one study has examined the use of the PSDSS in a population of OC patients with peritoneal carcinomatosis . In this multi‐institutional study, the prognostic value of the PSDSS was evaluated retrospectively in 553 patients with epithelial OC who received CRS/HIPEC.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the peritoneal surface disease severity score (PSDSS) in ovarian cancer patients undergoing cytoreductive surgery and HIPEC: Two pathogenetic types based study

Yarema

Fetsych

Volodko

et al. 2018

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The Cochrane review on the use of intraperitoneal (ip) chemotherapy for primary OC [58] concluded that this treatment prolonged PFS and OS. While there is evidence of a survival benefit for IP chemotherapy/HIPEC after cytoreductive surgery in primary disease, there are fewer reports on its use and efficacy in recurrent disease [59]. No mention was made of this type of treatment in the Cochrane review on recurrent ovarian cancer [60] nor in the review by the Fifth Ovarian cancer Consensus Conference of the Gynecologic Cancer InterGroup [7].…”

Section: Surgery and Ip/hipec Chemotherapy For Recurrent Ovarian Cancermentioning

confidence: 99%

Surgery for Recurrent Ovarian Cancer

Barton¹

2018

Ovarian Cancer - From Pathogenesis to Treatment

View full text Add to dashboard Cite

Most patients with ovarian cancer (OC) have the epithelial subtype (EOC) and present with advanced stage disease. Despite improved surgical and medical management of primary disease, the majority of patients will develop recurrence and ultimately die of disease. The current surgical goal in primary EOC is complete surgical cytoreduction (CSC) as this significantly improves disease-specific survival and overall survival. CSC is a major independent prognostic factor in primary EOC. Recurrent ovarian cancer (ROC) can be diagnosed in the symptomatic or in the asymptomatic patient on clinical evidence, tumour marker results and/or imaging. There are data from cases series and retrospective series on the role of surgery in ROC but there is not yet level I evidence of secondary surgical cytoreduction improving overall survival. The published data emphasise that, as with primary disease, the surgical goal is CSC. In selecting patients for secondary cytoreductive surgery a number of predictive models have been proposed and tested. Patients with ROC who have undergone CSC have a better prognosis than those treated with chemotherapy alone or those in whom the surgical goal was not achieved. The counter-argument is that there is bias in the surgical reports-those patients not operated on chemotherapy alone, or who had incomplete cytoreduction and/or who had chemotherapy had less favourable diseaseassociated and patient-associated factors than those who had CSC. To address these concerns, there are currently three ongoing randomised controlled trials on surgery for ROC.

show abstract

The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score

Cited by 22 publications

References 37 publications

Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures

Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures

Evaluation of the peritoneal surface disease severity score (PSDSS) in ovarian cancer patients undergoing cytoreductive surgery and HIPEC: Two pathogenetic types based study

Surgery for Recurrent Ovarian Cancer

Contact Info

Product

Resources

About